AU1045695A - Use of lobeline for the treatment of nicotine withdrawal - Google Patents

Use of lobeline for the treatment of nicotine withdrawal

Info

Publication number
AU1045695A
AU1045695A AU10456/95A AU1045695A AU1045695A AU 1045695 A AU1045695 A AU 1045695A AU 10456/95 A AU10456/95 A AU 10456/95A AU 1045695 A AU1045695 A AU 1045695A AU 1045695 A AU1045695 A AU 1045695A
Authority
AU
Australia
Prior art keywords
lobeline
nicotine
subject
sublingual
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU10456/95A
Other languages
English (en)
Inventor
Rajinder P. S Matharu
Indu A Muni
B. Ram Murty
Mahendra K Pandya
F. Howard Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DynaGen Inc
Original Assignee
DynaGen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/145,203 external-priority patent/US5414005A/en
Application filed by DynaGen Inc filed Critical DynaGen Inc
Publication of AU1045695A publication Critical patent/AU1045695A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Addiction (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Degasification And Air Bubble Elimination (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
AU10456/95A 1993-10-28 1994-10-28 Use of lobeline for the treatment of nicotine withdrawal Abandoned AU1045695A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14430993A 1993-10-28 1993-10-28
US08/145,203 US5414005A (en) 1993-10-28 1993-10-28 Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation
US145203 1993-10-28
US144309 1993-10-28
PCT/US1994/012442 WO1995011679A1 (en) 1993-10-28 1994-10-28 Use of lobeline for the treatment of nicotine withdrawal

Publications (1)

Publication Number Publication Date
AU1045695A true AU1045695A (en) 1995-05-22

Family

ID=26841884

Family Applications (2)

Application Number Title Priority Date Filing Date
AU10456/95A Abandoned AU1045695A (en) 1993-10-28 1994-10-28 Use of lobeline for the treatment of nicotine withdrawal
AU80960/94A Abandoned AU8096094A (en) 1993-10-28 1994-10-28 Use of nicotine substitutes for the treatment of nicotine withdrawal

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU80960/94A Abandoned AU8096094A (en) 1993-10-28 1994-10-28 Use of nicotine substitutes for the treatment of nicotine withdrawal

Country Status (6)

Country Link
EP (1) EP0725640A1 (cs)
JP (1) JPH09507053A (cs)
AU (2) AU1045695A (cs)
CA (1) CA2174747A1 (cs)
TW (1) TW261531B (cs)
WO (2) WO1995011678A1 (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018798A1 (en) 1996-10-30 1998-05-07 Pfizer Inc. Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
ES2141024B1 (es) * 1997-10-03 2000-10-16 Manzanares Jesus Mari Gonzalez Preparado de accion antinicotinica.
GB2376884A (en) * 2001-06-26 2002-12-31 Peter Hajek Helping smokers stop
CN1897882A (zh) * 2003-10-28 2007-01-17 阿尔扎公司 降低烟草使用频率的方法和装置
CN103284319A (zh) * 2013-06-20 2013-09-11 昌宁德康生物科技有限公司 一种金雀花碱替代尼古丁口腔雾化液及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1017032A (en) * 1963-12-12 1966-01-12 Aerosmoke Ltd Aerosol compositions
GB1056214A (en) * 1964-05-21 1967-01-25 Leo Baum Compositions containing lobeline sulphate
WO1983002892A1 (fr) * 1982-02-22 1983-09-01 Talapin, Vitaly, Ivanovich Preparation medicinale possedant un effet antinicotine et son procede d'obtention
US4665069A (en) * 1985-04-02 1987-05-12 Barnett Rosenberg Analgesic composition and method of relieving pain
GB2230439A (en) * 1989-04-20 1990-10-24 Alec Stanley Walter Shaw Nicotine lozenges

Also Published As

Publication number Publication date
WO1995011679A1 (en) 1995-05-04
JPH09507053A (ja) 1997-07-15
AU8096094A (en) 1995-05-22
WO1995011678A1 (en) 1995-05-04
CA2174747A1 (en) 1995-05-04
TW261531B (cs) 1995-11-01
EP0725640A1 (en) 1996-08-14

Similar Documents

Publication Publication Date Title
US6893654B2 (en) Two-stage transmucosal medicine delivery system for symptom relief
JP4358787B2 (ja) 改良されたニコチン舐剤
US6248760B1 (en) Tablet giving rapid release of nicotine for transmucosal administration
JP5845194B2 (ja) ニコチン含有ソフトゼラチントローチ
US20110268809A1 (en) Nicotine-Containing Pharmaceutical Compositions
Gourlay et al. Antismoking products
US20030022910A1 (en) Compositions and methods for sublingual formulations of dihydroergotamine for the treatment of migraine
US5480651A (en) Composition and method for treating nicotine craving in smoking cessation
US6645470B1 (en) Treatment and system for nicotine withdrawal
US5414005A (en) Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation
NZ281230A (en) Antitussue composition containing benzydamine used in conjunction with a centrally acting antitissue
WO2008124814A2 (en) Sublingual formulations of d-cycloserine and methods of using same
EP2029098A2 (de) Raucherentwöhnungs-kombinationswafer
AU1045695A (en) Use of lobeline for the treatment of nicotine withdrawal
US5880164A (en) Nicotine-free smoking material
WO1995011678A9 (en) Use of nicotine substitutes for the treatment of nicotine withdrawal
JPH0569093B2 (cs)
US20030198669A1 (en) Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
JP2000515548A (ja) ニコチン禁断症状を処置する方法
JPH07505367A (ja) 喫煙停止におけるニコチン渇望の処置のための副交感神経作用剤とムスカリン性拮抗剤との配合
WO1996029076A2 (en) Treatment of inflammatory bowel disorders with cotinine
CA2037353A1 (en) Method of self-administering a dopamine 2 receptor agonist